Matt Merguerian, MD, PhD

Primary Academic Title

Assistant Professor of Pediatrics

Background

Centers and Institutes

• Hemophilia Comprehensive Treatment Center
• Johns Hopkins Children's Center

LinkedIn

https://www.linkedin.com/in/merguerian/

Clinical Trial Keywords

Germline RUNX1 Deficiency; Familial Platelet Disorder

Clinical Trials Summary

Longitudinal Studies of Patient With FPDMM

ClinicalTrials.gov Identifier: NCT03854318

Contact for Research Inquiries

720 Rutland Avenue
Ross 1125
Baltimore, MD 21205

Phone: (410) 955-6132
Fax: (570) 473-5316

Research Interests

Inherited Thrombocytopenias, Platelet Function Disorders, Bone Marrow Failure Syndromes,

Research Summary

As an undergraduate at the University of Chicago, he worked in the lab of Dr. Shohei Koide using NMR spectroscopy to study how proteins bind to each other and how point mutations could interfere with this binding. Matt was then selected for an NIH NIGMS-funded spot in the Medical Scientist Training Program at Columbia University in New York City. There, he earned his medical degree at the Columbia College of Physicians and Surgeons, and he completed his doctoral studies in the laboratory of Dr. Virginia Cornish in the Department of Chemistry. In his doctoral research, he engineered a genetic system in yeast that could produce useful new binding proteins through a process of directed evolution. Dr. Merguerian then moved to New Haven, CT, where he trained in pediatrics as a resident at the Yale School of Medicine. He spent a research elective in the laboratory of Dr. Patrick Gallagher studying the GATA1 transcription factor. Dr. Merguerian then trained as a fellow in pediatric hematology/oncology at the combined Johns Hopkins / NIH program. At the NIH in Bethesda, MD, he worked in the lab of Dr. Paul Liu at the National Human Genome Research Institute (NHGRI). He is an associate investigator on the NIH natural history study of families with germline RUNX1 mutation, a condition which causes thrombocytopenia, platelet dysfunction, and increased risk of developing hematologic malignancy.

Google Scholar

https://scholar.google.com/citations?user=DkUrLQMAAAAJ

PubMed

https://pubmed.ncbi.nlm.nih.gov/?term=Merguerian+M&cauthor_id=38019014

Selected Publications

• Cunningham L*, Merguerian MD*, Calvo KR, Davis J, Deuitch NT, Dulau-Florea AE, Patel N, Yu K, Sacco K, Bhattacharya S, Passi M, Ozkaya N, De Leon SV, Chong SN, Craft KM, Diemer JL, Bresciani E, O'Brien KJ, Andrews EJ, Park N, Hathaway L, Cowen EW, Heller T, Ryan K, Barochia A, Nghiem K, Niemela JE, Rosenzweig SD, Young DJ, Frischmeyer-Guerrerio P, Braylan RC, Liu PP. Natural History Study of Patients with Familial Platelet Disorder with Myeloid Malignancy. Blood. 2023; 142(25): 2146-2158. *Co-first authors

• Liu, T, Merguerian, MD, Rowe, SP, Pratilas, CA, Chen, AR, Ladle, BH. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma. CSH Mol. Case Stud. 2021; 7(4):1-15

Courses & Syllabi

Organic Chemistry, Columbia University, New York, NY, 8/30/08 - 12/15/08

Honors

• Physician Scientist Training Program Scholar, Johns Hopkins University, 1/1/18
• Medical Scientist Training Program, NIH NIGMS, 1/1/08
• Frances E. Knock Prize for Outstanding Academic Achievement in Chemistry, University of Chicago, 1/1/06
• Howard Hughes Undergraduate Summer Research Fellowship, HHMI, 1/1/04
• Dean's List, University of Chicago, 1/1/03
• Robert C. Byrd Honors Scholarship, U.S. Dept. of Ed., 1/1/02

Memberships

• American Academy of Pediatrics,

  Fellow of the AAP